Milestone Pharmaceuticals Inc. (MIST)

Milestone Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	-	1	5	15	-
Revenue Growth (YoY)	-	-80.00%	-66.67%	-	-
Gross Profit	-	1	5	15	-
Selling, General & Admin	27.75	31.05	24.81	19.4	16.22
Research & Development	14.36	31.05	39.83	38.67	34.49
Operating Expenses	42.1	62.1	64.64	58.07	50.71
Operating Income	-42.1	-61.1	-59.64	-43.07	-50.71
Interest Expense	-3.58	-2.55	-	-	-
Interest & Investment Income	4.16	3.97	1.25	0.22	0.73
Pretax Income	-41.52	-59.69	-58.39	-42.85	-49.98
Income Tax Expense	-	-	-	-	-0.02
Net Income	-41.52	-59.69	-58.39	-42.85	-49.97
Net Income to Common	-41.52	-59.69	-58.39	-42.85	-49.97
Shares Outstanding (Basic)	62	43	42	42	29
Shares Outstanding (Diluted)	62	43	42	42	29
Shares Change (YoY)	44.82%	1.19%	1.47%	42.56%	85.91%
EPS (Basic)	-0.67	-1.39	-1.38	-1.02	-1.70
EPS (Diluted)	-0.67	-1.39	-1.38	-1.02	-1.70
Free Cash Flow	-28.88	-46.54	-52.74	-33.22	-50.73
Free Cash Flow Per Share	-0.46	-1.08	-1.24	-0.79	-1.73
Gross Margin	-	100.00%	100.00%	100.00%	-
Operating Margin	-	-6109.80%	-1192.84%	-287.15%	-
Profit Margin	-	-5968.50%	-1167.76%	-285.69%	-
Free Cash Flow Margin	-	-4653.60%	-1054.82%	-221.49%	-
EBITDA	-42	-61.01	-59.55	-42.98	-50.61
EBITDA Margin	-	-	-	-286.53%	-
D&A For EBITDA	0.11	0.09	0.09	0.09	0.1
EBIT	-42.1	-61.1	-59.64	-43.07	-50.71
EBIT Margin	-	-	-	-287.15%	-

Updated Mar 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q